This trial is designed to study the effects of a new drug, selpercatinib, on various types of solid tumors. The goal is to see if it is safe and tolerable, how it is metabolized, and if it has any preliminary anti-tumor activity.
3 Primary · 15 Secondary · Reporting Duration: Cycle 1 Day 1 through Cycle 5 Day 1 (Cycle = 28 days)
Experimental Treatment
875 Total Participants · 1 Treatment Group
Primary Treatment: LOXO-292 · No Placebo Group · Phase 1 & 2
Age Any Age · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: